low-grade-cervical-cytology-risk-comparable-to-normal-findings-in-follow-up-study
Low-Grade Cervical Cytology Risk Comparable to Normal Findings in Follow-up Study

Low-Grade Cervical Cytology Risk Comparable to Normal Findings in Follow-up Study

A large-scale nationwide cohort study in the Netherlands has revealed that women who are high-risk human papillomavirus (hrHPV) positive and present with persistent low-grade cervical cytological abnormalities have a low five-year cumulative incidence of cervical cancer. This risk profile was found to be numerically similar to the incidence observed among hrHPV-positive women who consistently tested negative for intraepithelial lesion or malignancy (NILM) at both their initial triage and one-year follow-up, a group currently discharged from further specialized monitoring within the Dutch national screening program. The findings, published in EClinicalMedicine, suggest that current risk-based management strategies may support further evaluation of less intensive follow-up protocols, although researchers emphasized that the results are hypothesis-generating and warrant validation in prospective studies with longer follow-up periods.

The study, which utilized data from the Dutch nationwide pathology database (Palga), included 22,891 hrHPV-positive women with low-grade triage cytological abnormalities—specifically atypical squamous cells of undetermined significance (ASC-US), atypical glandular cells of endocervical origin (AGC endocervical), or low-grade squamous intraepithelial lesions (LSIL)—detected between January 2017 and December 2018. The researchers aimed to assess the five-year cumulative incidence of cervical cancer in these subgroups, given the uncertainty regarding long-term outcomes for women with low-grade abnormalities who are managed within the national screening framework. For comparison, the investigators tracked 23,188 hrHPV-positive women who exhibited NILM cytology results at both baseline triage and one-year follow-up, representing a low-risk control group.

Statistical analysis indicated that the overall five-year cumulative incidence of cervical cancer among the 22,891 women with low-grade triage cytology was 0.47%, compared with 0.25% in the comparison group of women with persistent NILM results. Within the cohort of women with low-grade triage cytology, those who had ≤ cervical intraepithelial neoplasia (CIN) I at baseline colposcopy demonstrated a five-year cumulative incidence of 0.25%. Further risk stratification by one-year follow-up cytology showed that women with follow-up cytology results ≤ LSIL had an even lower incidence at 0.13%. Conversely, those with cytology results > LSIL at follow-up faced a significantly higher incidence of 1.45% over the five-year study period.

The research team identified baseline factors associated with higher risk, noting that women who developed cervical cancer during the study were slightly older, with a mean age of 41.8 years compared to 40.0 years for those who remained cancer-free. Furthermore, an AGC-endocervical result at initial triage was more frequent among the group that developed cervical cancer. Interestingly, the study found no significant difference in the prevalence of a prior history of abnormal cytology or histology between women who developed cancer and those who did not. This observation diverges from some previous research, and the authors suggest that differences in prior screening history and prior exposure to diagnostic testing could be contributing factors.

The timing of cervical cancer diagnosis also varied significantly across the different risk-stratified groups, providing insights into the progression of cervical disease. Among the 107 cases of cervical cancer identified, 30 were detected at the first examination following initial triage, predominantly within the first three months. For women classified with CIN II+ at baseline, 90% of the cancers were diagnosed within the first year. In contrast, among women with NILM at both triage and one-year follow-up, approximately 62% of the cervical cancers were diagnosed after the four-year mark of follow-up. These patterns illustrate that risk is not uniformly distributed throughout the five-year interval and remains dependent on the initial diagnostic findings and follow-up cytological status.

Despite the study’s strengths, including its large, population-based design and the use of centralized pathology data with comprehensive coverage, the researchers identified several limitations. Notably, they could not incorporate specific clinical and behavioral risk factors—such as hrHPV genotype, smoking status, sexual history, and immunodeficiency status—which could influence cervical cancer risk and act as residual confounders. Additionally, hrHPV testing was not repeated systematically during the follow-up period, meaning that the clearance or persistence of the initial hrHPV infection, a critical determinant of long-term risk, remained unmeasured. This limitation highlights the need for future studies to integrate longitudinal hrHPV testing for more precise risk stratification.

The potential for verification bias was also acknowledged as a challenge in the interpretation of the results. Because women with low-grade cytological abnormalities underwent immediate colposcopy, prevalent cervical cancer might have been detected earlier than in the comparison group of women with NILM, who were not referred for colposcopy at baseline. However, the researchers noted that by including a five-year follow-up period that encompassed the subsequent routine screening round, the study captured cancers that emerged after delayed diagnosis. The researchers maintained that their primary comparison—between those with confirmed ≤ CIN I histology at baseline and persistent low-grade cytology at follow-up versus those with persistent NILM results—occurred within a comparable framework that mitigated some of the risks of verification bias.

The researchers underscored that their results should be interpreted with appropriate caution, particularly in light of the hypothesis-generating nature of the data and the observed loss to follow-up, which affected 28.4% of the total cohort. Because clinical stage at diagnosis, specific treatment outcomes, and detailed prognosis were not available within the nationwide registry, the study’s scope remained focused on incidence rates. The team concluded that while their findings support the safety of current practices, moving toward less intensive management for women with persistent hrHPV and low-grade or negative cytology requires prospective, multi-center longitudinal evidence that incorporates clinical risk modifiers.

Ultimately, the study contributes critical outcome data to the ongoing discourse regarding the optimization of hrHPV-based screening programs. By demonstrating that specific subgroups within the low-grade cytology population exhibit risks comparable to those currently discharged to routine screening, the research provides a basis for future modeling of risk-based follow-up algorithms. Future investigations will need to weigh these findings against patient-reported outcomes, healthcare burden, and the cost-effectiveness of various management strategies to ensure that screening programs maximize early detection while minimizing unnecessary diagnostic procedures and overtreatment.

These longitudinal results from the Netherlands provide a standardized, population-level view of cervical cancer risk following initial hrHPV-based screening alerts. As screening programs worldwide move toward hrHPV-based protocols, the ability to tailor follow-up intensity based on individualized risk remains a primary goal. The study confirms that even among hrHPV-positive populations, the long-term risk of developing cervical cancer is stratified by persistence of cytological abnormalities and histological findings at baseline, paving the way for more nuanced, evidence-based management strategies in the future.

Beyond incidence rates, the pathology records provided detailed histological classifications for the 107 cervical cancers identified during the five-year follow-up period. Squamous cell carcinoma represented the dominant subtype, accounting for 72.0 percent (77 cases), followed by adenocarcinoma at 23.4 percent (25 cases). Invasive carcinoma not otherwise specified comprised 3.7 percent (4 cases), while anaplastic small cell carcinoma occurred in 0.9 percent (1 case). The researchers also tracked all-cause mortality across the cohort by linking pathology entries to national mortality data through the Central Bureau for Genealogy. During the five-year timeframe, overall mortality reached 2.8 percent (3 of 107) among women diagnosed with cervical cancer, compared with 0.7 percent (166 of 22,784) among those who remained cancer-free.

The nationwide registry analysis also characterized distinct subgroups within the low-grade cohort that encountered varying disease trajectories. Baseline colposcopy diagnosed cervical intraepithelial neoplasia grade II or higher in 17.4 percent of participants (3,993 women), who subsequently experienced a five-year cancer incidence of 1.50 percent (60 cases). Meanwhile, 5,275 women who had low-grade baseline cytology either lacked a scheduled one-year cytology test or returned nondiagnostic results; within this group, the five-year cumulative cancer incidence was 0.30 percent (16 cases). In post-hoc evaluations assessing adherence, loss to follow-up, defined as having no recorded cytology between 4.5 and 5.25 years after baseline, differed substantially among cohorts. Overall loss to follow-up reached 28.4 percent among women with initial low-grade triage cytology, spanning 24.5 percent in those with low-grade findings at one year, 24.2 percent in the higher-grade follow-up group, 28.0 percent among those with baseline high-grade lesions, and 38.6 percent among women missing one-year cytology. Among comparison participants with persistent negative cytology, 32.1 percent were lost to follow-up.

When contextualizing these observations within published literature, the study authors highlighted comparisons with earlier investigations across European screening programs. A previous study evaluating hrHPV-positive women with borderline or low-grade cytology documented an 11.4 percent five-year cumulative incidence of high-grade lesions without observing invasive cancers, while a Norwegian cohort reported three-year cumulative cervical cancer risks ranging between 0.4 percent and 1.5 percent for hrHPV-positive individuals with atypical cells or low-grade lesions. Because international screening frameworks handle follow-up differently, with several programs referring all hrHPV-positive women with negative cytology directly to colposcopy, the investigators cautioned that management conclusions cannot be broadly generalized without careful local validation. Given the baseline carcinomas detected during initial triage and discrepancies between cytology and histology, the authors maintained that colposcopic evaluation remains warranted following abnormal cytology and one year of follow-up, especially among patients exhibiting atypical endocervical glandular cells.

Subject of Research: Five-year cervical cancer incidence in hrHPV-positive women with low-grade cytological abnormalities.

Article Title: Incidence of cervical cancer in hrHPV-positive patients with low-grade cytological abnormalities: a Dutch nationwide cohort study

Article References: van de Kam, L., van Cooten, V., Piera, E., Siebers, A., de Leeuw, M., Bekkers, R., van Hamont, D., Speksnijder, L., & Piek, J. (2026). Incidence of cervical cancer in hrHPV-positive patients with low-grade cytological abnormalities: a Dutch nationwide cohort study. eClinicalMedicine, 102, Article 104337. https://doi.org/10.1016/j.eclinm.2026.104337

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104337

Keywords: Cervical Cancer, hrHPV, Screening Programs, Cytology, Cohort Study, Netherlands, Epidemiology, Risk Stratification, Follow-up, Pathology, Oncology, Public Health, Women’s Health, CIN, LSIL, NILM, Diagnostic Protocols